基本信息
浏览量:0
职业迁徙
个人简介
Ph.D. in Organic Chemistry from Universidad Autónoma de Madrid in 2011. In 2012 I joined the phytosanitary products research team at INIA, as a scientific advisor for the evaluation of new projects for the generation of plant-protecting products at the European level (EFSA). Since 2013, I have belonged to the Faculty of Pharmacy of the Universidad Complutense de Madrid (UCM), in the first 6 years as a Postdoctoral (PDI) and Senior Researcher (CIBBER-BBN) as part of the Smart Biomaterials Research Group (GIBI), actively contributing to nanomedicine research lines. During this age, I was focused on the synthesis and characterization of new functionalized hybrid bioactive nanomaterials based on Mesoporous Silica Nanoparticles (MSNs) with the aim of nano-medicine translational applications to oncologic therapies for neuroblastoma, bone cancer, and melanoma. Later, I assumed leadership in these research lines and introduced new lines focused on organic chemistry for the synthesis, characterization, and biological evaluation of new functionalized bioactive peptides, small molecules, and conjugates as new targeting agents for nano-drug discovery in oncology. During my stay in the GIBI group, I afforded 9 articles of high scientific impact, 1 European Patent, and 1 book chapter, as well as I was awarded the 2015 IDEA² Madrid Biomedical Technology Innovation Competition Award from Madrid-MIT M+ Vision Consortium, for our work in nanomedicine targeted treatment against neuroblastoma disease (Nano-drone). In 2019, I move to the MatNaBio Research Group in the same Faculty in the UCM, as a Senior Researcher, until I was afforded the Assistant Professor position. I started a new line inside this new group, focused on peptide and biomacromolecules and their nanomedicine application in bioimaging, immunotherapy, and autoimmune diseases. Recently, I afforded my first project as a PI granted by Ministerio de Ciencia e Inovación, focused on the development of new hybrid nanomaterials for bioimaging intending to evaluate immunotherapies in breast cancer. In this final stage, I afforded 4 high scientific impact factor articles, 2 Book Chapters, and 1 Editorial up to date. Otherwise, I have supervised uncountable students during my career; besides that, I was the director of 3 TFGs and 1 TFM, and already I am the Director of 2 Thesis dissertations, 2 TFGs, and 1 TFM. Briefly, I have authored 19 high scientific impact factor articles, 2 Book Chapters, and 1 European Patent. This yield has over 692 citations, with an H-index = 12 (Google Scholar, March.2023). I have officially participated in 10 research projects; belonging to the Scientific Team in 6 of them, being a leader within the research lines dedicated to the synthesis and biological characterization of biomolecules and hybrids nanomaterials for cancer theragnosis and being IP in the last one afforded, focused on the immunotherapies for breast cancer. I usually act as a reviewer for different journals, for instance, Polymers, Cancers, Pharmaceutics, Antioxidants, and Genes. Further, I was Guest Editor of a Special Issue titled Nanomaterials and Nanostructures for Biology in “Nanomaterials”. Finally, it is worth mentioning that, since 2019 I am an active member of the network for molecular imaging and nanomedicine in Madrid (RENIM).
研究兴趣
论文共 21 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ACS APPLIED POLYMER MATERIALS (2023)
Bioorganic & medicinal chemistry (2022): 116910-116910
Nanoscience & Nanotechnology SeriesReducing Agents in Colloidal Nanoparticle Synthesispp.1-27, (2021)
The Royal Society of Chemistry eBookspp.1-27, (2021)
引用0浏览0引用
0
0
21st Century Nanoscience – A Handbookpp.3-1, (2020)
ACS applied nano materialsno. 8 (2020): 8247-8256
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn